List of BsAbs used to treat malignancies
| Name . | Approval date . | Target . | Indication . |
|---|---|---|---|
| Blinatumomab | 2014 | CD3 × CD19 | ALL |
| Amivantamab | 2021 | MET × EGFR | Non–small cell lung cancer |
| Tebentafusp | 2022 | CD3 × HLA-A∗02:01 | Uveal melanoma |
| Teclistamab | 2022 | CD3 × BCMA | Multiple myeloma |
| Mosunetuzumab | 2022 | CD3 × CD20 | Follicular lymphoma |
| Epcoritamab | 2023 | CD3 × CD20 | Diffuse large B–cell lymphoma |
| Talquetamab | 2023 | CD3 × GPRC5D | Multiple myeloma |
| Glofitamab | 2023 | CD3 × CD20 | Diffuse large B–cell lymphoma |
| Name . | Approval date . | Target . | Indication . |
|---|---|---|---|
| Blinatumomab | 2014 | CD3 × CD19 | ALL |
| Amivantamab | 2021 | MET × EGFR | Non–small cell lung cancer |
| Tebentafusp | 2022 | CD3 × HLA-A∗02:01 | Uveal melanoma |
| Teclistamab | 2022 | CD3 × BCMA | Multiple myeloma |
| Mosunetuzumab | 2022 | CD3 × CD20 | Follicular lymphoma |
| Epcoritamab | 2023 | CD3 × CD20 | Diffuse large B–cell lymphoma |
| Talquetamab | 2023 | CD3 × GPRC5D | Multiple myeloma |
| Glofitamab | 2023 | CD3 × CD20 | Diffuse large B–cell lymphoma |
BCMA, B-cell maturation antigen; EGFR, epidermal growth factor; MET, mesenchymal epithelial transition factor.